title: Biodistribution and dosimetry of (iodine-123)-iodomethyl-N, N-diethyltamoxifen, an (anti)oestrogen receptor radioligand.
abstract: This study reports on the distribution and radiation dosimetry of iodine-123 labelled trans-Z-iodomethyl-N,N-diethyltamoxifen (123-ITX), a promising radioligand for prediction of the therapeutic efficacy of unlabelled tamoxifen in human breast carcinoma. Whole-body scans were performed up to 24 h after intravenous injection of 123-ITX (mean: 146 MBq, range: 142-148 MBq) in five female volunteers, four with and one without thyroid blockade. Blood samples were taken at various times up to 24 h after injection. Urine was also collected up to 24 h after injection, allowing calculation of renal clearance and interpretation of whole-body clearance. Time-activity curves were generated for the thyroid, heart, brain, breasts, liver and gallbladder by fitting the organ-specific geometric mean counts, obtained from regions of interest. The MIRD formulation was applied to calculate the absorbed radiation doses for various organs. The images showed rapid hepatobiliary excretion, resulting in good imaging conditions for the thoracic region, whereas imaging of the abdominal region was impeded by extensive bowel activity. The breast to non-specific uptake ratio increased over time. 123-ITX was cleared by both the kidneys and the gastrointestinal tract. At 50 h p.i. the mean excretion in the urine was 89.4% (SD 5.7%). If the thyroid was not blocked, it was one of the critical organs. The highest absorbed doses were received by the excretory organs, i.e. the urinary bladder wall, the lower and upper large intestine, and the gallbladder wall. The average effective dose of 123-ITX was estimated to be 0.0084 mSv/MBq. The amount of 123-ITX required for adequate imaging of tumoral uptake results in an acceptable effective dose to the patient.
authors.affiliation: Division of Nuclear Medicine, University Hospital Gent, De Pintelaan 185, B-9000 Gent, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Van de Wiele
authors.forename: F
authors.initials: F
authors.lastname: De Vos
authors.forename: J
authors.initials: J
authors.lastname: De Sutter
authors.forename: F
authors.initials: F
authors.lastname: Dumont
authors.forename: G
authors.initials: G
authors.lastname: Slegers
authors.forename: R A
authors.initials: RA
authors.lastname: Dierckx
authors.forename: H
authors.initials: H
authors.lastname: Thierens
mesh_terms: D000005:Abdomen / Q000000981:diagnostic imaging; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008875:Middle Aged; D017698:Postmenopause / Q000378:metabolism; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D011960:Receptors, Estrogen / Q000378:metabolism*; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014915:Whole-Body Counting
chemical_list: D004965:Estrogen Antagonists; D019275:Radiopharmaceuticals; D011960:Receptors, Estrogen; D013629:Tamoxifen; C403901:iodomethyl-N,N-diethyltamoxifen